Dosed multiple participants in Emboldenâ„¢ registrational trial in fourth quarter of 2025 Completion of dosing in Embolden expected in second quarter of 2026 ...
Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that Company management...
Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation...
Reported positive interim data from NGN-401 Phase 1/2 gene therapy trial for Rett syndrome demonstrating multidomain, durable gains, with 35 total developmental milestones/skills acquired...
Multidomain, durable gains with continued skill acquisition over time All 8 participants showed functional gains across spectrum of disease severity ...
Single trial to support future BLA submission for NGN-401 in patients ages ≥ 3 years Rapid trial execution underway with 12 of 13 clinical sites initiated ...
Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation...
In a report released today, Ryan Sigdahl from Craig-Hallum maintained a Buy rating on Neurogene. The company’s shares closed yesterday at $25.83.Elevate Your Investing Strategy: Take advantage of TipRanks...
Completed discussions with FDA on registrational protocol; 13 sites to allow for rapid enrollment New preclinical data at ESGCT Congress highlight NGN-401 best-in-class...